

## List of Figures

Figure No.	Title	Page No.
1.1.	The 10 leading causes of death in the world in 2012	5
1.2.	Schematic representations of various types of mobile genetic elements	14
1.3.	The structures of a class 1, class 2 and class 3 integrons	18
1.4.	Schematic diagram of chromosomal integron	20
1.5.	Toxin-Antitoxin system	23
1.6.	Horizontal gene transfer in bacterial population containing SXT element	26
3.1.	Agarose gel (1%) analysis of plasmid DNA samples from <i>V. fluvialis</i> BD146 and its transformants.	65
3.2.	Agarose gel (1%) analysis of plasmid profiles for BD146 transconjugants	67
3.3.	Schematic representation of class 1 integron from BD146.	69
3.4.	PCR amplification for class 1 integron/integrase-specific regions of BD146 and its transconjugants.	70
3.5.	Agarose gel analysis of PCR amplicons of <i>qnrVC</i> and <i>aac(6')-Ib-cr</i> from BD146, and its transformants and transconjugants.	72
3.6.	Schematic representation of plasmid pBD146.	75
3.7.	Agarose gel (1%) analysis of PCR amplicons of BDint from other clinical isolates of <i>V. fluvialis</i> , and transformants and transconjugants of BD146	77
3.8.	Comparison of BDint with other integrases	78
3.9.	Schematic representations of the predicted 3D structures of various tyrosine recombinases.	79
3.10.	Total genomic DNA from twelve clinical isolates of <i>Vibrio fluvialis</i>	86
3.11.	Agarose gel (1%) analysis of plasmid DNA from twelve clinical isolates of <i>Vibrio fluvialis</i>	87
3.12.	1% agarose gel analysis of plasmid DNA from <i>Vibrio fluvialis</i> isolates, their transformants, transconjugants, and recipient <i>E. coli</i> JM109, DH5 $\alpha$ and <i>V. cholerae</i> O1 El Tor N16961.	88
3.13.	Plasmid-mediated quinolone resistance	90

4.1.	Antibiotic susceptibility profile of clinical isolates of <i>Shigella flexneri</i> (a) and <i>Shigella sonnei</i> (b)	98
4.2	Year-wise percentage of drug resistance in <i>Shigella</i> isolates	99
4.3.	Dendrogram of <i>Xba</i> I- digested pulsed-field gel electrophoresis profiles of clinical isolates of <i>Shigella sonnei</i> .	101
4.4.	Dendrogram of <i>Not</i> I- digested pulsed-field gel electrophoresis profiles of clinical isolates of <i>Shigella flexneri</i> .	102
4.5.	Dendrogram of <i>Xba</i> I- digested pulsed-field gel electrophoresis profiles of clinical isolates of <i>Shigella boydii</i> .	103
4.6.	Dendrogram of <i>Xba</i> I- digested pulsed-field gel electrophoresis profiles of clinical isolates of <i>Shigella dysenteriae</i> .	103
4.7.	PCR analysis for class 1 integron	105
4.8.	PCR analysis for class 2 integron	106
4.9.	Agarose gel analysis (2%) of PCR products of <i>qnrS</i> gene	110
4.10.	Agarose gel analysis of quinolone resistance determining regions of topoisomerases.	111
4.11.	Plasmid DNA profile of <i>Shigella dysenteriae</i> and <i>Shigella boydii</i>	115
4.12.	Agarose gel analysis (1%) of plasmid DNA from representative <i>Shigella</i> spp., their transconjugants, and recipient <i>E. coli</i> XL1Blue and J53.	116

## List of Tables

Table No.	Title	Page No.
1.1.	Classes of antibiotics, their modes of action, their activity and examples	12
1.2.	Prevalence of mobile genetic elements in <i>Vibrio</i> spp. and <i>Shigella</i> spp.	31
2.1.	List of bacterial strains used	40
2.2.	List of antibiotics used for the analysis of antibiogram of <i>Vibrio fluvialis</i> and <i>Shigella</i> isolates	41
2.3.	Mixture for Pre-restriction incubation	46
2.4.	Mixture for restriction digestion	46
2.5.	PFGE conditions for <i>Vibrio fluvialis</i> and <i>Shigella</i> spp. restricted with <i>NotI</i> or <i>XbaI</i> enzyme.	47
2.6.	Primers used in the present study	50
2.7.	Ligation mixture for pDrive TA cloning	54
2.8.	Ligation mixture for pBAD TOPO TA cloning	55
2.9.	GenBank submissions made from the present study	56
3.1.	Antibiotic susceptibility pattern for <i>V. fluvialis</i> BD146 and its transformants in <i>E. coli</i> host JM109	65
3.2.	Determination of MIC values for the <i>Vibrio fluvialis</i> strain BD146 and its JM109 transformants.	66
3.3.	Antibiotic susceptibility profile of <i>Vibrio fluvialis</i> BD146 and its transconjugants.	67
3.4.	Evaluation of extended spectrum beta lactamase activity in <i>V. fluvialis</i> BD146 isolate	73
3.5.	Evaluation of efflux pump activity in <i>V. fluvialis</i> BD146 isolate	74
3.6.	Predicted ORFs of pBD146	75
3.7.	Correlation of resistance to different antibiotics with corresponding genes/factors in clinical isolate of <i>V. fluvialis</i> BD146	84
3.8.	Antibiograms of clinical isolates of <i>Vibrio fluvialis</i> from 2006	85
3.9.	Antibiotic susceptibility patterns of <i>Vibrio fluvialis</i> parent isolates, their transformants and transconjugants	88
3.10.	Topoisomerase mutations in quinolone resistance determining regions of <i>Vibrio fluvialis</i> isolates	89

3.11.	Synergy test for efflux pump activity in <i>Vibrio fluvialis</i> isolates	91
3.12.	Evaluation of extended spectrum beta lactamase activity in <i>V. fluvialis</i> isolates	91
4.1.	Antibiotic susceptibility profiles of <i>Shigella dysenteriae</i> and <i>Shigella boydii</i> isolates	99
4.2.	Presence of integrons in <i>Shigella</i> isolates.	107
4.3.	Integron analysis in <i>Shigella</i> isolates	109
4.4.	Topoisomerase mutations in quinolone resistance determining regions of <i>Shigella</i> isolates.	113
4.5.	Efflux pump activity in <i>Shigella</i> isolates by synergy test	114
4.6.	Transferable resistance traits of transconjugants from <i>Shigella</i> isolates	116